Zobrazeno 1 - 10
of 355
pro vyhledávání: '"Ashutosh, D Wechalekar"'
Autor:
Efstathios Kastritis, Arpit Misra, Laura Gurskyte, Florint Kroi, Andre Verhoek, Jessica Vermeulen, Eric Ammann, Annette Lam, Sarah Cote, Ashutosh D. Wechalekar
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTObjectives: Amyloid light-chain (AL) amyloidosis is a rare disease characterized by amyloid fibril deposits made up of toxic light chains causing progressive organ dysfunction and death. Recent studies suggest that hematologic response may be
Externí odkaz:
https://doaj.org/article/4c7982a23cd841e7bbdd0d78214e0fd9
Autor:
Jahanzaib Khwaja, Joshua Bomsztyk, Shameem Mahmood, Brendan Wisniowski, Raakhee Shah, Anish Tailor, Kwee Yong, Rakesh Popat, Neil Rabin, Charalampia Kyriakou, Jonathan Sive, Simona Degli Esposti, Daniel F. P. Larkin, Sarah Worthington, Alyse Hart, Emma Dowling, Nuno Correia, Ceri Bygrave, Andrzej Rydzewski, Krzysztof Jamroziak, Ashutosh D. Wechalekar
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 9, Pp 1-3 (2022)
Externí odkaz:
https://doaj.org/article/e4d4b37586d0442ea1202150bfb9a084
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Autor:
Sriram Ravichandran, Oliver C. Cohen, Steven Law, Darren Foard, Marianna Fontana, Ana Martinez-Naharro, Carol Whelan, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Philip N. Hawkins, Ashutosh D. Wechalekar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)
Abstract The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here we report the impact of speed of response in a cohort of AL
Externí odkaz:
https://doaj.org/article/b337fd1300e6447c92566346cf8407bf
Autor:
Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong, Prashant Kapoor
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US a
Externí odkaz:
https://doaj.org/article/013c38376a484b75ab2ff3152ca40fbf
Autor:
Catherine S. Y. Lecat, Jessica B. Taube, William Wilson, Jonathan Carmichael, Christopher Parrish, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Neil K. Rabin, Jonathan Sive, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a chal
Externí odkaz:
https://doaj.org/article/824d4c0c5b7c4fb48057514e0769e341
Autor:
Tamer Rezk, Janet A Gilbertson, P Patrizia Mangione, Dorota Rowczenio, Nigel B Rendell, Diana Canetti, Helen J Lachmann, Ashutosh D Wechalekar, Paul Bass, Philip N Hawkins, Vittorio Bellotti, Graham W Taylor, Julian D Gillmore
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 5, Iss 3, Pp 145-153 (2019)
Abstract The tissue diagnosis of amyloidosis and confirmation of fibril protein type, which are crucial for clinical management, have traditionally relied on Congo red (CR) staining followed by immunohistochemistry (IHC) using fibril protein specific
Externí odkaz:
https://doaj.org/article/9387814b13b64cdd87bd2fdab0cb78d9
Autor:
Kenshi Suzuki, Ashutosh D. Wechalekar, Kihyun Kim, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, Chang-Ki Min, Fude Zhou, Zhen Cai, Xiaonong Chen, Shinsuke Iida, Nagaaki Katoh, Tomoaki Fujisaki, Ho-Jin Shin, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brenda Tromp, Brendan M. Weiss, Raymond L. Comenzo, Efstathios Kastritis, Jin Lu
Publikováno v:
Annals of Hematology. 102:863-876
Subcutaneous daratumumab plus bortezomib/cyclophosphamide/dexamethasone (VCd; D-VCd) improved outcomes versus VCd for patients with newly diagnosed immunoglobulin light-chain (AL) amyloidosis in the phase 3 ANDROMEDA study. We report a subgroup analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13d1483e4c96069e91be6f7da44c103a
https://doi.org/10.1007/s00277-023-05090-z
https://doi.org/10.1007/s00277-023-05090-z
Autor:
Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan O. Schönland, Heather J. Landau, Fiona Kwok, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Dasha Cherepanov, Vanessa C. Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis
Publikováno v:
American Journal of Hematology. 98:720-729
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81385dee2b681fd549f28bb89f3cb3a7
https://doi.org/10.1002/ajh.26866
https://doi.org/10.1002/ajh.26866
Autor:
Faye A. Sharpley, Marianna Fontana, Ana Martinez-Naharro, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Carol J. Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
Patients with systemic immunoglobulin light chain amyloidosis (AL) with no evidence of cardiac involvement by consensus criteria have excellent survival, but 20% will die within 5 years of diagnosis and prognostic factors remain poorly characterised.
Externí odkaz:
https://doaj.org/article/4c0d2fdc319441b7ad5798507526abd1
Autor:
Monique C. Minnema, Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh D. Wechalekar, Martha Grogan, Ronald Witteles, Frederick L. Ruberg, Mathew S. Maurer, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Arnaud Jaccard
Publikováno v:
JACC: CardioOncology. 4:474-487
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5752e191e1b1efaf189a2a58987ef686
https://doi.org/10.1016/j.jaccao.2022.08.011
https://doi.org/10.1016/j.jaccao.2022.08.011